Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. Click here to find out why RVMD ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

"The gene can have a mutation, which I happen to have," said ... "These are the so-called RAS inhibitors." Research indicates that RAS inhibitors target a specific protein that signals the body ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation ... blocks cancer cells' wild type RAS membrane localization, prohibiting ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations. “The ...